Avantor (AVTR) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Avantor (AVTR) right now is Revival transformation program: Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. Revenue (FY2025) is ~$6.55B. If that keeps playing out, the setup is favourable; the risk to it is avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. No one can predict where AVTR trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Avantor (AVTR) higher?
1. Revival transformation program
Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. Q1 2026 results exceeded expectations partly on this self-help, and a new Chief Transformation Officer (Ludovic Brellier, hired from Danaher's Cytiva) was brought in to run the effort. Success here is the central swing factor for margins over the next several years.
2. Recurring consumables and bioprocessing exposure
A large portion of Avantor's sales are repeat-purchase consumables tied to ongoing lab and manufacturing activity rather than one-time capital equipment. Its Bioscience Production exposure (single-use assemblies, chromatography resins, excipients) links it to biologics and vaccine production, a structurally growing end market. This recurring base gives revenue relative stability once destocking and customer caution normalize.
3. End-market normalization
The soft patch across life sciences tools has been driven by post-pandemic inventory destocking and tighter biopharma and academic budgets. As those pressures ease, Avantor is positioned to return to organic growth. Management framed 2026 as a stabilization year, with organic revenue guided to roughly flat to slightly down and improvement expected as comparisons ease.
4. Free cash flow and deleveraging
Avantor generates substantial free cash flow (guided to roughly $500 million to $550 million for 2026), which it is directing toward reducing net leverage from above 3x adjusted EBITDA. Steady debt paydown would lower interest costs and financial risk, improving the equity's risk profile even before any strong top-line acceleration.
What could weigh on AVTR?
Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (adjusted net leverage above 3x), which amplifies the downside if EBITDA disappoints and constrains flexibility. It reported GAAP net losses tied to write-downs, and the turnaround depends heavily on execution by a leadership team still being reshaped. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.
Where AVTR trades today
A forecast starts from where the stock actually is. These are AVTR's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for AVTR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a AVTR forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the AVTR guide and whether AVTR is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the AVTR outlook
The bottom line: what is driving Avantor (AVTR) is Revival transformation program, with revenue (fy2025) at ~$6.55B. If that keeps playing out the setup is favourable; the risk is avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. No one can predict the price, so treat any AVTR forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around AVTR with Walnut
Use Avantor as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Avantor (AVTR)?
+
No one can reliably predict where AVTR will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Avantor higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive AVTR higher?
+
The main growth drivers are Revival transformation program; Recurring consumables and bioprocessing exposure; End-market normalization. Whether they play out is the real question, not a guaranteed path.
What are the risks to AVTR?
+
Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (adjusted net leverage above 3x), which amplifies the downside if EBITDA disappoints and constrains flexibility. It reported GAAP net losses tied to write-downs, and the turnaround depends heavily on execution by a leadership team still being reshaped. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.
Will AVTR stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Avantor's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is AVTR a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the AVTR "is it a buy?" page for a framework. Walnut is not an investment adviser.
What is Avantor's 2026 guidance?
+
For 2026 Avantor guided to organic revenue roughly flat to down a few percent, adjusted EPS of about $0.77 to $0.83, and free cash flow of roughly $500 million to $550 million. Management has framed 2026 as a stabilization year ahead of a potential return to growth.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.